AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis. To study the safety and tolerability of a hyperimmune goat serum product (AIMSPRO) in the treatment of systemic sclerosis (SSc) through a period of 26 weeks of study participation. The secondary objective of the study is to assess the efficacy of AIMSPRO as a therapeutic agent for SSc using inter alia the SSc-HAQ questionnaire and the modified Rodnan skin score. ClinicalTrials.gov. (Also see: Clinical Trials)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
AIMSPRO in Diffuse Cutaneous Systemic Sclerosis
No replies to this topic